Format

Send to

Choose Destination
Mod Rheumatol. 2014 Jul;24(4):685-7. doi: 10.3109/14397595.2013.874734. Epub 2014 Feb 11.

Successful treatment of eosinophilic granulomatosis with polyangiitis (EGPA; formerly Churg-Strauss syndrome) with rituximab in a case refractory to glucocorticoids, cyclophosphamide, and IVIG.

Author information

1
Department of Medicine and Rheumatology, Graduate School of Medicine and Dental Science, Tokyo Medical and Dental University , Tokyo , Japan.

Abstract

A 44-year old woman with eosinophilic granulomatosis with polyangiitis (EGPA) developed sequential paralysis of different cranial nerves despite treatments including methylpredonisolone pulse therapy, intravenous immunoglobulins (IVIG), and cyclophosphamide. Infusions of rituximab ameliorated her neurological symptoms and serological inflammatory findings. Rituximab, a specific B cell-targeting therapy, might offer an alternative for refractory EGPA with possible advantages of cost and ease of use compared to IVIG, which also targets (at least in part) B lymphocytes and immunoglobulin production.

KEYWORDS:

Eosinophilic granulomatosis with polyangiitis; IVIG; Rituximab

PMID:
24517553
DOI:
10.3109/14397595.2013.874734
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center